Guardant Health Inc (GH) Return on Equity ROE from the third quarter 2026 to third quarter 2025 and annually, average high and low, overall ranking from Sep 30 2026 to Sep 30 2025 - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Guardant Health Inc   (NASDAQ: GH)
    Sector • Healthcare    Industry • Medical Laboratories
   Industry • Medical Laboratories
   Sector • Healthcare

Guardant Health Inc 's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics


What is ROE for Guardant Health Inc in the third quarter 2026?
Due to the lack of equity, it was not possible to calculate Guardant Health Inc 's return on equity (ROE) in its third quarter 2026

What is ROE?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Equity (Sep 30 2026)
III. Quarter		 (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter
Y / Y Equity Change - - - - -
Y / Y Net Income Change - - - - -
Net Income (TTM) in Millions -485 -453 -433 -416 -399
Return On Equity (TTM) - - - - -
GH's Total Ranking # # # # #
Equity (TTM) in Millions -276 -223 -181 -99 -354
Seq. Equity Change - - - - -
Seq. Net Income Change - - - - -

Back to GH Management Effectiveness >> GH's 5 Years Annual ROE >> Compare GH ROE to its Competitors
Return On Equity Company Ranking
Within: No.
Industry #
Sector #
Overall #

Return On Equity Statistics
High Average Low
0 %
0 %
0 %
 





GH Annual Return On Equity (Dec 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021
Total Equity in Millions -99 -140 159 60 645
Y / Y Equity Change - - 163.68 % -90.67 % -50.33 %
Net Income in Millions -416 -436 -479 -655 -385
Y / Y Net Income Change - - - - -
Return On Equity - - -302.14 % -1087.72 % -59.65 %

Back to GH Management Effectiveness >> GH's 5 Years Annual ROE >> Compare GH ROE to its Competitors




More Return On Equity Ratios
Medical Laboratories Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
GH's' Return on Equity at Yahoo Finance
GH's Roe Ratio versus Medical Laboratories Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for GH's Competitors
Subscribers only: Roe for Guardant Health Inc 's Suppliers
Subscribers only: Return On Equity for GH's Customers




Companies with similar Return On Equity at Sep 30 2026, within Healthcare Sector ROE
Halozyme Therapeutics Inc   544.26 %
Elutia Inc   267.71 %
Alnylam Pharmaceuticals Inc   159.72 %
Amneal Pharmaceuticals Inc   157.05 %
Sanuwave Health Inc   142.86 %
Arbutus Biopharma Corp  129.13 %
Alector Inc   112.21 %
Medpace Holdings Inc   99.76 %
3m Company  93.07 %
Exelixis Inc   85.83 %
Amgen Inc   85.59 %
Eli Lilly And Company  83.65 %
Rigel Pharmaceuticals Inc  73.94 %
Idexx Laboratories Inc  71.18 %
Tenet Healthcare Corp  57.13 %
Aurinia Pharmaceuticals Inc   51.92 %

Date modified: 2026-11-06T13:00:22+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.